You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 718 AMG 509, a STEAP1 x CD3 bispecific XmAb® 2+1 immune therapy, exhibits avidity-driven binding and preferential killing of high STEAP1-expressing prostate and Ewing sarcoma cancer cells

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Novel single-agent immunotherapies
718 AMG 509, a STEAP1 x CD3 bispecific XmAb® 2+1 immune therapy, exhibits avidity-driven binding and preferential killing of high STEAP1-expressing prostate and Ewing sarcoma cancer cells

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020161027
Dec 202061011
Jan 202137014
Feb 202129016
Mar 202162017
Apr 202159017
May 202122016
Jun 20211016
Jul 20210015
Aug 20211020
Sep 2021008
Oct 202150024
Nov 202126030
Dec 202118011
Jan 202226024
Feb 202240023
Mar 2022102018
Apr 2022132028
May 2022114035
Jun 202282014
Jul 202296016
Aug 2022146016
Sep 202274013
Oct 202298011
Nov 2022104014
Dec 2022118017
Jan 2023144026
Feb 2023134017
Mar 2023166033
Apr 2023124030
May 2023172027
Jun 2023126023
Jul 2023432024
Aug 2023272037
Sep 2023264029
Oct 2023578084
Nov 2023362067
Dec 2023180034
Jan 202490018
Feb 2024190032
Mar 2024314045
Apr 2024234052
May 2024252044
Jun 2024232042
Jul 2024452046
Aug 2024244023
Sep 2024296045
Oct 2024214052
Nov 2024238055
Dec 2024275055
Jan 2025194056
Feb 202562054
Mar 20250035
Apr 20250035
May 20250032
Jun 20250019
Total790001642